Home | Find A Doctor | Contact Us

 

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

Principal Investigator: Peter Kozuch, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

Summary:
This study aims to test the effectiveness and safety of GS-6624 at different dose levels. GS-6624 is an experimental agent being developed to treat many different diseases. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic pancreatic adenocarcinoma when it is given with Gemcitabine. Gemcitabine is approved by the FDA for pancreatic adenocarcinoma.

Eligibility of Participants:
• 18 years of age or older
• Initial diagnosis of metastatic disease must have occurred = 6 weeks prior to the completion of the screening
• The presence of measurable metastatic pancreatic cancer documented by CT or MRI

Please call for more information.

 

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System